A research team from HKUMed has developed QUIZOM, a novel combination therapy for AML with FLT3 mutations, achieving an 83% CRc rate and reducing relapse risk.
A research team from the Department of Medicine at the LKS Faculty of Medicine, University of Hong Kong (HKUMed), has introduced a groundbreaking novel combination therapy that significantly enhances treatment outcomes and survival rates for patients suffering from acute myeloid leukemia (AML) with FLT3 gene mutations. The study, published in a leading medical journal, revealed that combining the FLT3 inhibitor Quizartinib with the protein synthesis inhibitor Omacetaxine Mepesuccinate (QUIZOM) effectively curtails cancer cell proliferation and stimulates the patient's immune system.
The combined therapy achieved a composite complete remission (CRc) rate of approximately 83%, marking a substantial improvement over traditional treatments. Importantly, this innovative approach also reduces the likelihood of leukemia relapse, providing patients with a more extended window for potential bone marrow transplants if necessary. The research team's findings suggest that QUIZOM could be a pivotal advancement in the management and treatment of AML, offering hope to those affected by this aggressive blood cancer.
"This study represents a significant leap forward in our understanding of FLT3-mutated AML," commented Dr. Li Hua, lead researcher from HKUMed. "The combination of Quizartinib and Omacetaxine Mepesuccinate not only targets the root cause of the disease but also enhances the body's natural defenses against cancer cells."
The study underscores the potential for QUIZOM to become a standard treatment regimen in the future, potentially transforming the landscape of leukemia care. As Dr. Hua noted, "Our findings indicate that this novel combination therapy could be life-changing for many patients with AML, offering them new hope and improved quality of life."
